AbCellera Biologics (ABCL) Other Working Capital Changes (2020 - 2026)

AbCellera Biologics has reported Other Working Capital Changes for 7 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 123.78% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$8.1 million (up 52.09% YoY), and the FY2025 full-year result was -$17.1 million, down 188.01% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $1.7 million, up from -$3.1 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $16.7 million in Q2 2025, with the low at -$23.4 million in Q3 2025.
• Historically, Other Working Capital Changes has averaged -$2.2 million across 5 years, with a median of -$3.1 million in 2025.
• The largest YoY upside for Other Working Capital Changes was 2036.84% in 2024 against a maximum downside of 1598.13% in 2024.
• AbCellera Biologics' Other Working Capital Changes stood at $5.5 million in 2022, then slumped by 354.78% to -$13.9 million in 2023, then jumped by 64.5% to -$4.9 million in 2024, then jumped by 37.93% to -$3.1 million in 2025, then jumped by 156.71% to $1.7 million in 2026.
• The last three Other Working Capital Changes figures came in at $1.7 million (Q1 2026), -$3.1 million (Q4 2025), and -$23.4 million (Q3 2025), per Business Quant data.